脑机接口+CRO概念+传感器+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 2、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站式服务。 来源：新浪证券-红岸工作室 2月27日，美好医疗涨3.89%，成交额4.59亿元，换手率3.98%，总市值177.89亿元。 异动分析 技术面：筹码平均交易成本为32.71元 该股筹码平均交易成本为32.71元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 31.02，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 3、根据2025年9月22日互动易：公司自研压力传感器和NO电化学传感器分别用于肺功能仪和哮喘检测 仪产品，毫米级电磁定位传感器也在自主开发中，相关产品的业务规模较小。 4、公司的主营业务是医疗器械精密组件及产品的设计开发、制造和销售。公司主要产品为家用呼吸机 组件、人工植入耳蜗组件和 ...

Core Viewpoint - The company, 美好医疗, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Performance - 美好医疗's stock rose by 6.57% with a trading volume of 860 million yuan and a turnover rate of 6.75%, leading to a total market capitalization of 19.842 billion yuan [1]. - The company reported a revenue of 1.194 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% [7][8]. - The company has a significant overseas revenue contribution, accounting for 86.64% of total revenue, benefiting from the depreciation of the yuan [3]. Group 2: Business Operations - 美好医疗 is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with a focus on home respiratory machine components, cochlear implant components, and pulmonary function instruments [2][7]. - The company is actively collaborating with downstream brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is still small [2]. - 美好医疗 has initiated the construction of automated production lines for weight loss pen orders, expected to be delivered next year [2]. Group 3: Market Dynamics - The company is categorized under the medical device sector, with its main products including home respiratory machine components (59.48% of revenue), consumer electronics components (14.61%), and other medical product components [7]. - The stock has shown signs of accumulation, with an average trading cost of 32.84 yuan, and is approaching a resistance level of 35.00 yuan, indicating potential for upward movement if this level is breached [6].

Group 1 - The core viewpoint of the news is that Meihao Medical has seen a stock price increase of 5.13%, reaching 34.41 yuan per share, with a trading volume of 464 million yuan and a turnover rate of 3.71%, resulting in a total market capitalization of 19.575 billion yuan [1] - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The revenue composition of Meihao Medical includes: 59.48% from home respiratory machine components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, 5.63% from precision molds and automation equipment, 1.09% from other categories, and 0.70% from proprietary products [1] Group 2 - Among the top circulating shareholders of Meihao Medical, Penghua Fund's Penghua New Emerging Industries Mixed A (206009) increased its holdings by 63,000 shares in the third quarter, now holding 3.5758 million shares, which accounts for 2.29% of the circulating shares [2] - The Penghua New Emerging Industries Mixed A fund, established on June 15, 2011, has a latest scale of 3.215 billion yuan, with a year-to-date return of 10.88% and a one-year return of 50.4% [2] - The fund manager, Liang Hao, has a tenure of 14 years and 219 days, with a total fund asset scale of 10.837 billion yuan, achieving a best return of 354.33% and a worst return of -31.55% during his tenure [2]

Core Viewpoint - The company, 美好医疗, is experiencing growth in its medical device sector, with a focus on brain-machine interface collaborations and weight loss products, while benefiting from the depreciation of the Chinese yuan. Group 1: Company Performance - 美好医疗's stock increased by 2.35% with a trading volume of 343 million yuan and a market capitalization of 18.619 billion yuan [1] - The company reported a revenue of 1.194 billion yuan for the first nine months of 2025, representing a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [7][8] - The company has distributed a total of 293 million yuan in dividends since its A-share listing [9] Group 2: Business Operations - The company is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with major products including home respiratory machine components and cochlear implant components [2][7] - 美好医疗's overseas revenue accounted for 86.64% of total revenue, benefiting from the depreciation of the yuan [3] - The company is collaborating with brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is small [2] Group 3: Market Position and Shareholder Information - The company has a diverse shareholder base, with 29,800 shareholders as of January 30, 2025, and an average of 12,536 circulating shares per person [7] - Major shareholders include 国泰聚信价值优势灵活配置混合A and 华宝中证医疗ETF, with some new institutional investors entering the top shareholder list [9]

脑机接口+CRO概念+减肥药+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 异动分析 来源：新浪证券-红岸工作室 2、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站式服务。 2月10日，美好医疗跌1.31%，成交额1.88亿元，换手率1.59%，总市值180.50亿元。 3、2025年10月22日投资者关系记录表：公司已与客户签订减肥笔订单，相关自动化产线已启动建设， 预计明年投入交付。 公司简介 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-1645.77万，占比0.09%，行业排名129/137，该股当前无连续增减仓现象，主力趋势不 明显；所属行业主力净流入-3.33亿，连续2日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-1645.77万-2813.67万-379 ...

来源：新浪证券-红岸工作室 2月2日，美好医疗跌1.13%，成交额3.17亿元，换手率2.72%，总市值174.70亿元。 异动分析 脑机接口+减肥药+CRO概念+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 资金分析 今日主力净流入-700.69万，占比0.02%，行业排名93/135，连续2日被主力资金减仓；所属行业主力净流 入-6.62亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-700.69万1250.93万-5495.78万4979.78万-6.99亿 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.24亿，占总成交额的6.75%。 2、2025年10月22日投资者关系记录表：公司已与客户签订减肥笔订单，相关自动化产线已启动建设， 预计明年投入交付。 3、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站 ...

Group 1 - The core viewpoint of the news is that Meihao Medical's stock price increased by 5.32% to 33.09 CNY per share, with a trading volume of 161 million CNY and a turnover rate of 1.33%, resulting in a total market capitalization of 18.824 billion CNY [1] - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, and specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The revenue composition of Meihao Medical includes: 59.48% from home respiratory machine components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, 5.63% from precision molds and automation equipment, 1.09% from other categories, and 0.70% from proprietary products [1] Group 2 - Among the top circulating shareholders of Meihao Medical, Penghua Fund's Penghua New Emerging Industries Mixed A (206009) increased its holdings by 63,000 shares in the third quarter, now holding 3.5758 million shares, which accounts for 2.29% of the circulating shares [2] - The fund has a latest scale of 3.215 billion CNY, with a year-to-date return of 10.77%, ranking 2169 out of 8866 in its category, and a one-year return of 53.75%, ranking 1970 out of 8126 [2] - The fund manager, Liang Hao, has a tenure of 14 years and 204 days, with a total asset scale of 10.837 billion CNY, achieving the best fund return of 359.7% and the worst return of -31.55% during his tenure [2]

1月26日，美好医疗跌5.46%，成交额5.96亿元。两融数据显示，当日美好医疗获融资买入额4868.64万 元，融资偿还5884.57万元，融资净买入-1015.93万元。截至1月26日，美好医疗融资融券余额合计3.21 亿元。 融资方面，美好医疗当日融资买入4868.64万元。当前融资余额3.19亿元，占流通市值的1.74%，融资余 额超过近一年90%分位水平，处于高位。 分红方面，美好医疗A股上市后累计派现2.93亿元。 机构持仓方面，截止2025年9月30日，美好医疗十大流通股东中，国泰聚信价值优势灵活配置混合A （000362）位居第二大流通股东，持股591.79万股，为新进股东。华宝中证医疗ETF（512170）位居第 三大流通股东，持股481.27万股，相比上期减少88.13万股。香港中央结算有限公司位居第五大流通股 东，持股371.34万股，相比上期增加71.48万股。国泰金牛创新成长混合（020010）位居第六大流通股 东，持股361.79万股，为新进股东。鹏华新兴产业混合A（206009）位居第七大流通股东，持股357.58 万股，相比上期增加6.30万股。博时医疗保健混合A（050026 ...

Group 1: Brain-Computer Interface (BCI) Business - The company is a leading global partner and core supplier in the cochlear implant sector, with nearly 15 years of deep collaboration in technology development and production transformation [2] - The company aims to provide comprehensive technical and product support across invasive, semi-invasive, and non-invasive BCI routes, reinforcing its competitive edge in invasive BCI implants [2] - Current revenue from the BCI business (excluding cochlear implant components) is relatively small, indicating investment risks [2] Group 2: Robotics Business - The company is actively developing humanoid robots and has initiated product technology layouts in collaboration with clients, leveraging its expertise in PEEK materials and small motor components [3] - In the surgical robot sector, the company has begun small-scale deliveries to domestic and international clients [3] Group 3: Shareholding and Financial Management - A total of 14,274,464 shares are proposed to be reduced, accounting for 2.51% of the total share capital, with 2.00% through block trading and 0.51% through competitive bidding [4] - The management emphasizes maintaining shareholder value through transparent and efficient operational strategies [4] Group 4: Injection Pen and Continuous Glucose Monitoring (CGM) Business - The company has successfully delivered adjustable insulin injection pens in bulk and signed orders for weight loss pens, with automated production lines expected to be operational in 2026 [5] - CGM products are set to enter mass delivery in Q2 2025, currently in a stable ramp-up phase, with further capacity expansion planned for 2026 [5] Group 5: Respiratory and Cochlear Implant Components - The company provides comprehensive design, development, manufacturing, and sales services for precision components and products in the medical device sector, aiming to be a global leader in medical technology services [6] - Long-term strategic partnerships with leading global companies in the home ventilator and cochlear implant markets have been established, ensuring continuous innovation and competitive advantages [7]

Core Viewpoint - The company, Shenzhen Meihao Chuangyi Medical Technology Co., Ltd., is focusing on the development and commercialization of medical devices, particularly in the fields of brain-machine interfaces, PEEK materials, and CRO services, while benefiting from the depreciation of the RMB [2][4]. Group 1: Business Overview - The company's main business involves the design, development, manufacturing, and sales of precision components and products for medical devices, with key products including home ventilator components, cochlear implant components, and pulmonary function instruments [3][8]. - The revenue composition of the company includes 59.48% from home ventilator components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, and 5.63% from precision molds and automation equipment [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.194 billion yuan, representing a year-on-year growth of 3.28%, while the net profit attributable to the parent company was 208 million yuan, showing a year-on-year decrease of 19.25% [9]. - The company's overseas revenue accounted for 86.64% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Market Activity - On January 14, the company's stock price fell by 2.32%, with a trading volume of 1.332 billion yuan and a turnover rate of 9.79%, resulting in a total market capitalization of 20.383 billion yuan [1]. - The main capital inflow for the day was -116 million yuan, indicating a reduction in main capital positions over the past two days [5][6]. Group 4: Shareholder Information - As of December 19, the number of shareholders was 15,300, a decrease of 1.74% from the previous period, with an average of 24,335 circulating shares per person, an increase of 1.77% [9][10]. - The second-largest circulating shareholder is Guotai Junan Value Advantage Flexible Allocation Mixed Fund, holding 5.9179 million shares, while several new shareholders have entered the top ten list [10].